Urology
Volume 70, Issue 6, Supplement 1 , Pages S27-S35 , December 2007

Appropriate Patient Selection in the Focal Treatment of Prostate Cancer: The Role of Transperineal 3-Dimensional Pathologic Mapping of the Prostate—A 4-Year Experience

  • Winston E. Barzell

      Affiliations

    • Urology Treatment Center, Sarasota, Florida, USA
    • Corresponding Author InformationReprint requests: Winston E. Barzell, MD, 1921 Waldemere, Suite 310, Sarasota, Florida 34239.
    • Dr. Barzell is a consultant for CIVCO Medical Solutions.
    • ,
  • Myron R. Melamed

      Affiliations

    • Department of Pathology, New York Medical College, Valhalla, New York, USA
    • Dr. Melamed has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.

References 

  1. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from the U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–990
  2. Carter HB. Prostate cancers in men with low PSA levels—must we find them?. N Engl J Med. 2004;350:2292–2294
  3. Carroll PR. Early stage prostate cancer—do we have a problem with over-detection, overtreatment or both?. J Urol. 2005;173:1061–1062
  4. Barnes RW. Survival with conservative therapy. JAMA. 1969;210:331–336
  5. Whitmore WF, Warner KA, Thompson IM. Expectant management of localized prostate cancer. Cancer. 1991;67:1091–1095
  6. Carter HB, Walsh PC, Landis P, et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002;167:1231–1234
  7. Carter CA, Donahue T, Sun L, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21:4001–4008
  8. Messing EM, Thompson I. Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol Clin North Am. 2003;30:687–702
  9. Allaf ME, Carter HB. AUA Update Series: The Results of Watchful Waiting for Prostate Cancer. In: Houston, Texas: American Urological Association; 2005;p. 24;Lesson 1
  10. Onik G, Narayan P, Vaughn D, et al. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60:109–114
  11. Onik G. The Male Lumpectomy: A Rational New Approach to Treating Prostate Cancer. Bloomington, Indiana: AuthorHouse; 2004;
  12. Masson P, Prepelica KL, Lambert EH, et al. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. J Urol. 2005;173:179
  13. Rukstalis DB, Goldknopf JL, Crowley EM, et al. Prostate cryoablation: a scientific rationale for future modifications. Urology. 2002;60:19–25
  14. Grossklaus DJ, Coffey CS, Shappell GS, et al. Prediction of tumor volume and pathological state in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int. 2001;88:722–726
  15. D’Amico AV, Wu Y, Chen M, et al. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤7. Cancer. 2000;89:1810–1817
  16. Mian BM, Lehr DJ, Moore CK, et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology. 2006;67:379–383
  17. Furuya Y, Fuse H, Nagakawa O, et al. Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer. Int J Clin Oncol. 2002;7:109–113
  18. Anast JW, Andriole GL, Bismar TA, et al. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?. Urology. 2004;64:544–550
  19. Freedland SJ, Aronson WJ, Terris MK, et al. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2003;98:2344–2350
  20. DiMarco DS, Bludt ML, Zincke H, et al. Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less. Urol Oncol. 2003;21:439–446
  21. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol. 2003;170:370–372
  22. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (state T1c) prostate cancer. JAMA. 1994;271:368–374
  23. Barzell WE, Whitmore WF. Transperineal template guided saturation biopsy of the prostate: rationale, indications and technique. Urology Times. 2003;31:41–42
  24. Barzell WE, Melamed MR. A solution to the over-detection and potential over-treatment of clinically insignificant prostate cancer. 2006;In the process of submission for publication
  25. Igel TC, Knight MK, Young PR, et al. Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. J Urol. 2001;165:1575–1579
  26. Pinkstaff DM, Igel TC, Petrou P, et al. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology. 2005;65:735–739
  27. Emiliozzi P, Corsetti A, Federico G, et al. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology. 2003;61:961–966
  28. Takefumi S, Matsumoto K, Fujita T, et al. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology. 2005;66:114–118
  29. Chon CH, Lai FC, McNeal JE, et al. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol. 2002;167:2457–2460
  30. Naya Y, Atsushi O, Troncoso P, et al. A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer. J Urol. 2004;171:2203–2208
  31. Borboroglu PG, Comer SW, Riffenburgh RH, et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 2000;163:158–162
  32. Fleshner N, Klotz L. Role of “saturation biopsy” in the detection of prostate cancer among difficult diagnostic cases. Urology. 2002;60:93–97
  33. Sved PD, Gomez P, Monoharan M, et al. Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol. 2004;172:98–102
  34. King CR, McNeal JE, Gill H, et al. Extended prostate biopsy scheme improves reliability of Gleason grading: implication for radiotherapy patients. Int J Radiat Oncol Biol Phys. 2004;59:386–391
  35. Stewart CS, Leibovich BC, Weaver AL, et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166:86–92
  36. Halpern EJ, Frauscher F, Strup SE, et al. Prostate: high frequency Doppler US imaging for cancer detection. Radiology. 2002;225:71–77
  37. Dhingsa R, Qayyum A, Coakley FV, et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging effect of clinical data on reader accuracy. Radiology. 2004;230:215–220
  38. Chun FK, Steuber T, Erbersdobler A, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol. 2006;49:820–826
  39. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small moderately differentiated, confined tumors. J Urol. 2003;170:1792–1797
  40. Onik GM, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291–1299
  41. Pisters LL, von Eschenbach AC, Scott SM, et al. Efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157:921–925
  42. Wong WS, Chin DO, Chin M, et al. Cyrosurgery as treatment for prostate carcinoma: results and complications. Cancer. 1997;79:963–974
  43. Katz AE, Gefar M. Selection of salvage cryotherapy patients. Rev Urol. 2002;4(suppl 2):18–23
  44. de la Taille A, Hayek O, Benson MC, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology. 2000;55:79–84
  45. Lam JS, Belledegrun AS. Salvage cryosurgery of the prostate after radiation failure. Rev Urol. 2004;6(suppl 4):27–36

PII: S0090-4295(07)01792-X

doi: 10.1016/j.urology.2007.06.1126

Urology
Volume 70, Issue 6, Supplement 1 , Pages S27-S35 , December 2007

Article Tools

* Image Usage & Resolution